findmyKOL
Clinical trialNCT06362369RecruitingPhase 1/PHASE2Interventional

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Sponsor7 Hills Pharma, LLCEnrollment126ALK Genomic Tumor AberrationsAdvanced CancerAdvanced Solid TumorAnaplastic Lymphoma Kinase Genomic Tumor AberrationsColorectal CancerHepatocellular Cancer+12 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Colorado Cancer Center

    Aurora, Colorado, United States

    Sapna Patel, MD
    Recruiting
  • Florida Cancer Specialists

    Lake Mary, Florida, United States

    Completed
  • Dartmouth Hitchcock

    Lebanon, New Hampshire, United States

    Konstantin H Dragnev, MD
    Recruiting
  • Brown University Health Cancer Institute

    Providence, Rhode Island, United States

    Recruiting
  • Md Anderson Cancer Center

    Houston, Texas, United States

    Apostolia-Maria Tsimberidou, MD, PhD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AlintegimodIpilimumab →Nivolumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
23 Aug 2024
Primary completion
31 Dec 2027
Completion
31 Dec 2028
Last update posted
13 Apr 2026
Registered enrollment
126
Registry id
NCT06362369
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.